Q3 2021 Financial Presentation2021-11-04 The Executive Managment in Ascelia Pharma presents a business update and the quarterly results InvestorGenväg till IR & Media IR & Media Key downloads Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for ReviewQuarterly Report Q3 2025: Orviglance NDA Submitted to the FDAHalf-Year Report 2025: Orviglance NDA Submission ApproachingQuarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission
